- |||||||||| Lymphomun (FBTA05) / Trion Pharma, NeoPharm, solitomab (AMG 110) / Amgen, Kalbitor (ecallantide) / Takeda
Journal: Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds. (Pubmed Central) - Oct 14, 2021
Novel multivalent Ab scaffolds (e.g., MDX-447, MT110, CD20Bi, TF2, and FBTA05) and mimetic Abs (e.g., Adnectin, DARPins, Ecallantide) offer improved pharmacokinetic and pharmacodynamic properties. Here, we discuss the avidity and multivalency and provide comprehensive insights into advanced Ab scaffolds used for immunotargeting and therapy of cancer.
- |||||||||| Lymphomun (FBTA05) / Trion Pharma, NeoPharm
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: STP-LYM-01: Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Dec 5, 2015
P1/2, N=9, Terminated,
Here, we discuss the avidity and multivalency and provide comprehensive insights into advanced Ab scaffolds used for immunotargeting and therapy of cancer. N=30 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Mar 2016; Recruitment delayed, trial medication no loner available
|
